TrialRheumatology (Oxford, England)2021

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients.

Luurssen-Masurel Nathalie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.